N/A
Completed N=41
Application of Economics & Social Psychology to Improve Opioid Prescribing Safety (AESOPS): R21 Pilot Phase
Opioid Use, Unspecified
Source: ClinicalTrials.gov NCT03773484 ↗
Enrolled (actual)
41
Serious AEs
0.0%
Results posted
Aug 2022
Primary outcomePrimary: Average Weekly Milligram Morphine Equivalent (MME) — 34.62; 22.37; NA Weekly MME per clinician — p=0.43
Summary
There is a lack of evidence that long-term opioid use offers benefit for noncancer pain and an abundance of evidence of harm. The objective of the R21 pilot phase of the Application of Economics & Social psychology to improve Opioid Prescribing Safety (AESOPS) is to develop and test novel behavioral nudges to encourage adherence to pain and CDC guidelines for opioid prescribing for persons with noncancer pain. Interventions will leverage the electronic health record (EHR) to discourage unnecessary opioid prescribing through the application of "behavioral insights"-empirically-tested social and psychological interventions that affect choice.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Average Weekly Milligram Morphine Equivalent (MME) |
34.62; 22.37; NA | 0.43 |
Eligibility Criteria
Inclusion Criteria
- NM clinic that sees patients ≥ 18 years old whose leadership agrees to participate
Exclusion Criteria
- None
Data sourced from ClinicalTrials.gov (NCT03773484). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.